Clinical Trial Update: Safety and Efficacy of PSMA-Targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Robot-Assisted Radical Prostatectomy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating DGPR1008, a PSMA-targeted fluorescent contrast agent, for intraoperative imaging during robot-assisted radical prostate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DGPR1008

Snippet

Sponsor: Zhu Yinjie | Conditions: Prostate Cancer | Phase 2 | Status: NOT_YET_RECRUITING